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The MDM2 oncoprotein ubiquitinates and antago-
nizes p53 but may also carry out p53-independent
functions. Here we report that MDM2 is required for
the efficient generation of induced pluripotent stem
cells (iPSCs) from murine embryonic fibroblasts, in
the absence of p53. Similarly, MDM2 depletion in
the context of p53 deficiency also promoted the dif-
ferentiation of human mesenchymal stem cells and
diminished clonogenic survival of cancer cells.
Most of the MDM2-controlled genes also responded
to the inactivation of the Polycomb Repressor Com-
plex 2 (PRC2) and its catalytic component EZH2.
MDM2 physically associated with EZH2 on chro-
matin, enhancing the trimethylation of histone 3 at
lysine 27 and the ubiquitination of histone 2A at lysine
119 (H2AK119) at its target genes. Removing MDM2
simultaneously with the H2AK119 E3 ligase Ring1B/
RNF2 further induced these genes and synthetically
arrested cell proliferation. In conclusion, MDM2
supports the Polycomb-mediated repression of line-
age-specific genes, independent of p53.
INTRODUCTION
The tumor suppressor p53 has long been known as the most
‘‘successful’’ tumor suppressor gene, based on the fact that a
majority of human cancers rely on its mutation. Recent cancer
genome analyses confirmed this notion (Olivier et al., 2010).
The MDM2 oncoprotein is the best-characterized cellular antag-
onist of p53. It forms a specific complex with p53, represses68 Molecular Cell 61, 68–83, January 7, 2016 ª2016 Elsevier Inc.p53-induced transcription, and triggers ubiquitination and sub-
sequent degradation of p53 via its RING finger-mediated E3
ligase activity. The gene encoding MDM2 is subject to amplifica-
tion in some cancers (Oliner et al., 1992). Even more frequently,
however, the MDM2 antagonist p14ARF is suppressed in human
malignancies, leading to MDM2 hyperactivation and p53 inhibi-
tion (Zhang et al., 1998). Many additional regulators and
signaling pathways functionally interact with MDM2, thereby
placing it as an integrator of networks to govern p53 activity
(Wade et al., 2013).
The genes encoding p53 and MDM2 were among the first to
be disrupted in a targeted fashion in mice (‘‘knockout’’ mice).
The disruption of p53 does not grossly affect development but
gives rise to cancer (Donehower et al., 1992). In contrast, disrup-
tion of MDM2 alone is embryonic lethal, while p53/MDM2 double
knockout mice are viable and display a similar phenotype as the
p53 single knock-outs (Jones et al., 1995; Montes de Oca Luna
et al., 1995). This gave rise to two important but perhaps
oversimplified conclusions: (1) p53 is not required for proper
development and (2) MDM2 has only one important biological
function, i.e., antagonizing p53.
In addition to p53, a number of additional interaction partners
and/or ubiquitination substrates for MDM2 have been described
(Bohlman and Manfredi, 2014; Marine and Lozano, 2010). How-
ever, little is known about the role of these interaction partners in
the biological activities of MDM2, e.g., in MDM2-driven
oncogenesis.
Reprogramming somatic cells to adopt a stem cell phenotype
has broadened the perspectives of tissue regeneration. The
most widely used protocol for obtaining induced pluripotent
stem cells (iPSCs) employs a combination of three or four vec-
tors for ectopic expression of Oct4, Sox2, Klf4, and (frequently)
c-Myc (Takahashi and Yamanaka, 2006). An increasing number
of genes were identified that need to be expressed en-
dogenously (not ectopically) for iPSC generation. Of note,
(legend on next page)
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chromatin-modifying factors were found to support iPSC gener-
ation; in particular, the Polycomb Repressor Complex 2 (PRC2)
is necessary for iPSC formation (Onder et al., 2012). PRC2 re-
presses differentiation-associated genes, including the Hox
gene clusters (Shah and Sukumar, 2010), by triggering the trime-
thylation (me3) of histone 3 at lysine 27 (H3K27me3). It thereby
helps to confer a stem-like phenotype to its host cell (Margueron
and Reinberg, 2011) and is strictly required for the development
of an organism (O’Carroll et al., 2001). PRC2 functionally inter-
acts with another chromatin-modifying complex termed Poly-
comb Repressor Complex 1 (PRC1). PRC1 monoubiquitinates
histone 2A at lysine 119 (H2AK119ub1), thus repressing genes
to promote stemness (Boyer et al., 2006). PRC2-mediated
H3K27 trimethylation was initially considered a prerequisite for
subsequent H2AK119 ubiquitination (Cao et al., 2002), but
more recently, situations were identified where H2AK119 mono-
ubiquitination occurs independent of H3K27me3 (Farcas et al.,
2012; He et al., 2013; Tavares et al., 2012; Wu et al., 2013) or
even precedes H3K27 trimethylation (Blackledge et al., 2014;
Cooper et al., 2014; Hu et al., 2012; Kalb et al., 2014). Thus, a
scenario of mutual enhancement of the two modifications and
their associated PRC activities is emerging.
Stem cell-like properties are also associated with cancer cells
(Gupta et al., 2009). Accordingly, PRC2 activity not only en-
hances the stem cell characteristics of normal cells but often
also confers enhanced cancer aggressiveness, e.g., in glioblas-
toma (Natsume et al., 2013). Conversely, suppression of PRC2
members, e.g., by microRNA 101 targeting the PRC2 compo-
nent EZH2, antagonizes tumor growth (Varambally et al.,
2008). Activating mutations of Ezh2 were identified in lym-
phomas; this revealed the PRC2 complex as a potential thera-
peutic target, currently investigated in clinical trials (McCabe
et al., 2012).
Despite the fact that mouse development was largely unaf-
fected by the loss of p53, p53 still represents a strong modulator
of iPSC generation. Murine embryonic fibroblasts (MEFs) that
lack p53 can be reprogrammed to become iPSCs with much
greater efficiency (Krizhanovsky and Lowe, 2009).
Given the roles of p53 and PRC2 in iPSC generation, the ques-
tion arises whether they or their regulatory partners might func-
tionally and/or physically interact. Interestingly, the ability of
MDM2 to monoubiquitinate H2A at K119 has been observed
in vitro (Minsky and Oren, 2004). We therefore asked whether
MDM2 can cooperate with or even replace PRC functions in his-
tone ubiquitination. First, we sought to determine the p53-inde-
pendent impact of MDM2 on iPSC generation. Comparing
p53/ MEFs with p53/MDM2/ double knockout MEFs re-Figure 1. Mdm2 Is Required for Efficient iPS Cell Generation and PRC2
(A) p53/ and p53/Mdm2/MEFs were reprogrammed into induced pluripote
obtained iPS colonies per MEFs was determined (mean ± SEM, n = 3).
(B) p53/, p53/ Mdm2/, and p53/ Mdm2CA/CA (Mdm2CA/CA = Mdm2C462A
entially expressed genes are shown as a heatmap (ordered by p values).
(C) qRT-PCR analysis of selected genes (mean ± SEM, n = 4).
(D) Ezh2was inhibited by 48 hr incubation with 5 mMEPZ6438, followed by qRT-PC
Note that the fold change values between DMSO- and EPZ6438-treated cells ar
and Ezh2.
See also Figure S1 and Table S1, Table S2, Table S3, and Table S4.
70 Molecular Cell 61, 68–83, January 7, 2016 ª2016 Elsevier Inc.vealed that the absence of MDM2 strongly reduced the effi-
ciency of iPSC generation. Similar p53-independent functions
of MDM2 in supporting stemness were also identified in mesen-
chymal stem cells, and in cancer cells. Moreover, MDM2 physi-
cally associated with the PRC2 complex, acting as a cofactor in
the suppression of PRC2 target genes and enhancing both
H3K27 trimethylation as well as H2AK119 monoubiquitination
at these genes. This points to a p53-independent role of
MDM2 in promoting cell stemness by supporting polycomb
repressor functions.
RESULTS
Mdm2 Is Required for the Efficient Generation of
Pluripotent Stem Cells from p53-Deficient Murine
Embryonic Fibroblasts, and for the Repression of PRC2-
Regulated Genes
p53 represents a barrier to the reprogramming of somatic cells.
At first glance, this appears to explain why Mdm2 activation by
the removal of p19ARF facilitates the induction of pluripotent
stem cells from wild-type MEFs, similar to the removal of p53
itself (Li et al., 2009; Utikal et al., 2009). However, to test whether
Mdm2 also fulfills a p53-independent function during induced
pluripotency, we compared the efficiency of iPSC induction in
MEFs prepared from mice lacking either p53 alone (p53/) or
both p53 and Mdm2 (p53/Mdm2/). These cells were trans-
duced with various combinations of retroviruses expressing
Oct4, Sox2, or Klf4, and the numbers of pluripotent cell clones
were determined. This number dropped between 6- and
12-fold in p53/Mdm2/ MEFs when compared with p53/
MEFs, regardless of the factor combination used (Figure 1A
and see Figure S1A available online). A considerable albeit less
pronounced difference in efficiency was also observed when
generating iPSCs from wild-type MEFs versus p53/ MEFs
(Figure S1A). RNA sequencing analysis revealed numerous
differentially regulated genes between p53/ and
p53/Mdm2/ MEFs, with enrichments of gene sets involved
in development and morphogenesis (Figures 1B; Table S1,
tabs 1 and 3; Table S2; and Table S3). Differential regulation
was partially persistent during reprograming, reflected by sepa-
rate clustering of p53/ and p53/Mdm2/ cells regardless of
pluripotency (Figures S1B and S1C). A mutation of the RING
finger domain in Mdm2 (Itahana et al., 2007), compared to a
complete deletion of Mdm2 (Montes de Oca Luna et al., 1995)
affected these expression patterns in a similar way (Figures 1B
and 1C; Table S2; p53/Mdm2C462A/C462A; abbreviated
p53/Mdm2CA/CA from here on). This suggests that theTarget Gene Repression in Murine Embryonic Fibroblasts
nt stem (iPS) cells by three factors (Oct4, Sox2, and Klf4; OSK). The number of
/C462A) MEFs were analyzed via next-generation RNA sequencing, and differ-
R (mean ± SEM, n = 5). Above the bars, fold change and p values are indicated.
e consistently lower in p53/ Mdm2/ MEFs, suggesting epistasis of Mdm2
ubiquitin ligase function of the RING finger is required for modu-
lating gene expression. The lack of Mdm2 led to increased
expression of genes that govern cell type specification, e.g.,
members of the Hox B and C clusters, as confirmed individually
(Figure 1C). Intriguingly, Gene set enrichment analysis (GSEA) of
all genes upregulated by the absence of Mdm2 indicated a
correlation with Polycomb Repressor Complex 2 (PRC2)-regu-
lated and H3K27 trimethylated gene sets (Figure S1D; Table
S1, tab 6; Table S4). In contrast, the negatively regulated genes
were enriched for stem cell-specific and H3K4me3-associated
genes (Figure S1E; Table S1, tab 6; Table S4; qRT-PCR;
Figure S1F).
Hox genes represent a paradigm for regulation by the PRC2 in
the context of development (Steffen and Ringrose, 2014) as well
as cancer (Shah and Sukumar, 2010), and H3K27me3 is strongly
associated with these gene clusters (Ho et al., 2011). We there-
fore tested whether PRC2 might regulate an overlapping set of
genes. Indeed, a pharmacological inhibitor of PRC2 activity,
EPZ-6438 (Knutson et al., 2013), led to the expected reduction
in overall H3K27 trimethylation (Figure S1G) and enhanced the
expression of Hox genes that were also induced by Mdm2 inac-
tivation (Figure 1D). Of note, the relative degree of gene activation
by EPZ-6438 was less pronounced in cells that already lacked
Mdm2, at least suggesting thatMdm2andPRC2act epistatically.
Thus,Mdm2 strongly contributes to the induction of pluripotency
in the absence of p53, regulating PRC2-related gene sets.
Removal of MDM2 Promotes the Differentiation of
Human Mesenchymal Stem Cells and Regulates Genes
Similar to the Knockdown of EZH2
Next, we asked whether MDM2 also contributes to the fate of
nonpluripotent stem cells in a p53-independent fashion. Human
mesenchymal stem cells (MSCs) were transfected with siRNAs
to knock down p53, MDM2, or both in combination (Figures
S2A and S2B). For comparison, we also depleted EZH2, the
enzymatically active component of PRC2, which was shown to
suppress the differentiation of MSCs (Wei et al., 2011). Following
induction of differentiation to the osteoblast lineage MDM2
depletion increased osteoblast differentiation, as indicated by
alkaline phosphatase activity (Figures 2A and 2B) and the
expression of alkaline phosphatase (ALPL) and osteocalcin
(BGLAP) (Figure 2C). Since p53 activity was augmented in
response to MDM2 depletion (Figure S2A; upregulation of p21/
CDKN1A), it would be conceivable to assume a role of p53 in
enhanced differentiation. In seeming agreement, removing p53
alone substantially suppressed differentiation. Importantly, how-
ever, while depleting p53, the additional depletion of MDM2 still
promoted cell differentiation to a similar degree as following indi-
vidual knockdown of either MDM2 or EZH2. We conclude that
MDM2 supports the maintenance of stemness in MSCs, and
its removal promotes differentiation independent of p53. Of
note, consistent with a role in stemness, the levels of MDM2
mRNA decreased during osteoblastic differentiation of MSCs
(Figure S2C).
Gene expression analysis revealed that expression profiles in
MDM2-depleted conditions clustered together regardless of the
presence of p53 (Figure 2D; Table S5). Moreover, removing
EZH2 resulted in a similar pattern, with a large overlap of differ-entially expressed genes, as confirmed by principal component
analysis (component 1, Figure S2D). The vast majority of these
genes were regulated in the same direction by EZH2 or MDM2
knockdown (Figure 2E), as confirmed individually for the osteo-
blast specific genes BMP4 and IGF2 as well as the known
PRC2 target genes TIMP3 and GDF6 (Sher et al., 2012; Shin
and Kim, 2012; Twine et al., 2014) (Figure 2F). In contrast, we
found only small overlaps of coregulated genes when comparing
MDM2/EZH2-dependent genes with those that responded to
p53 knockdown, alone (Figure S2E) or in the context of p53 in-
duction (Figures S2F and S2G). Genes upregulated (but not
downregulated) by depletion of MDM2 or EZH2 were highly en-
riched for functions in development and differentiation (Table S1,
tabs 2 and 4; Table S3). Differentially expressed genes in p53/
MDM2 knockdown osteoblasts (compared to siCtrl) revealed a
similar enrichment of H3K27me3- and PRC2-associated gene
sets as observed in the MEF system (Table S1, tab 7; Table
S4). Taken together, MDM2 and EZH2 repress an overlapping
set of genes to limit the osteoblastic differentiation of MSCs.
MDM2 Is Required for the Clonogenic Survival of Cancer
Cells, Even in the Absence of Functional p53
Tumor cells frequently adopt or retain the self-renewal capacity
as seen in stem cells. Moreover, epigenetic plasticity supports
self-renewal (Easwaran et al., 2014), raising the possibility that
MDM2 may contribute to cancer cell survival through chromatin
modification. To test this, we depleted MDM2 from colon carci-
noma-derived HCT116 cells with a genetic ablation of p53 (Bunz
et al., 1998). For comparison, siRNA to EZH2 was transfected,
which is known to interfere with the proliferation of these cells
(Fussbroich et al., 2011). Strikingly, the knockdown of either
MDM2 or EZH2 similarly diminished the proliferation of
HCT116 p53/ cells (Figures 3A and S3A). A comparable
dependence of clonogenic survival on MDM2 was also found
in MCF7 cells (breast carcinoma) and the osteosarcoma cell
line SJSA, even upon p53 depletion, and in Panc1 cells (pancre-
atic carcinoma, mutant p53) (Figures 3B and S3B–S3G). Hence,
MDM2 confers an essential function to the growth of tumor cells
even in the absence of functional p53.
Next, we monitored gene expression levels in HCT116 cells
lacking p53 following knockdown of either MDM2 or EZH2 (Fig-
ure 3C; Table S6). While only a limited set (149) of genes was
responsive to MDM2 knockdown, the removal of EZH2 yielded
a larger number of differentially regulated genes (1,565). Strik-
ingly, however, a majority (68%) of the MDM2-regulated genes
were also affected by the removal of EZH2 (Figure 3D). Of these
genes, all showed the same direction in the change of their
expression levels following either MDM2 or EZH2 depletion.
Genes that were upregulated upon MDM2 depletion were en-
riched for H3K27me3-associated genes; downregulated genes
were associated to some extent with stemness (Table S1,
tab 8; Table S4). qRT-PCR confirmed the regulation of selected
PRC2 target genes following MDM2 depletion both in HCT116
(Figures 3E and S3H) as well as MCF7 cells (Figure 3F). While in-
dividual genes were rarely altered in all three cell systems (MEFs,
MSCs, HCT116p53/), we did identify gene sets by GSEA that
were enriched in all three cases and characterized byH3K27me3
(Table S1, tabs 6–8). In conclusion, apart from its role inMolecular Cell 61, 68–83, January 7, 2016 ª2016 Elsevier Inc. 71
Figure 2. MDM2 Hinders the Differentiation of Human Mesenchymal Stem Cells to Osteoblasts and Contributes to the Regulation of PRC2
Target Genes
(A) hMSC-Tert cells were depleted of MDM2 and/or p53 or EZH2 using siRNA, followed by the addition of osteoblast differentiation medium. At day 7, alkaline
phosphatase (AP) activity was detected.
(B) Quantification of AP activity from A (mean ± SEM, n = 3).
(C and D) RNA from the differentiated osteoblasts was quantified by qRT-PCR (C, n = 3) and array hybridization. (D, n = 2; the genes are shown that were
differentially regulated with the highest significance.)
(E) Venn diagrams present overlapping gene sets that respond to EZH2 and MDM2 and p53 depletion.
(F) qRT-PCR analysis of marker genes (mean ± SEM, n = 3).
See also Figure S2 and Table S1, Table S3, Table S4, and Table S5.
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Figure 3. MDM2 Represses PRC2 Target Genes and Promotes Survival of Tumor Cells
HCT116 p53/ and MCF7 cells were depleted of MDM2 and EZH2.
(A) HCT116 p53/ cells were transfected at the time points 0 and 48 hr. At 96 hr, the cells were trypsinized and then seeded at equal numbers, followed by
analysis of their proliferation. Either depletion reduces the proliferation of HCT116 p53/ cells (mean ± SEM, n = 3).
(B) The amount of MCF7 cells displaying clonogenic survival was reduced by depletion of MDM2 or EZH2, too, regardless of p53 coknockdown (mean ± SEM,
n = 3).
(C) Differential gene expression was determined via microarray analysis of HCT116 p53/ cells. (n = 2; the most significantly regulated genes are shown; two
different siRNAs were used for each gene)
(legend continued on next page)
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antagonizing p53, a major activity of MDM2 consists in govern-
ing a subset of PRC2-regulated genes in tumor cells as well as
stem cells.
MDM2 Physically Associates with the PRC2 Members
EZH2 and SUZ12 and Is Recruited to PRC2 Target Gene
Promoters by EZH2
Comprehensive gene expression analysis suggested thatMDM2
acts as a cofactor for PRC2-mediated gene regulation. We
therefore tested whether MDM2 might be capable of forming a
complex with the PRC2. Immunoprecipitation of endogenous
MDM2 as well as the PRC2 components EZH2 and SUZ12 re-
sulted in reciprocal coprecipitation (Figure 4A), strongly suggest-
ing that MDM2 and PRC2 physically associate. Furthermore,
transiently overexpressed and immunoprecipitated MDM2 was
found to bind EZH2 (Figure 4B) as well as SUZ12 (Figure 4C).
The interaction of transiently expressed Mdm2 with Ezh2 was
also detected in a murine system (Figure S4A). In addition, we
coprecipitated the PRC2 member EED with Mdm2 upon tran-
sient coexpression, specifically in the presence of EZH2
(Figure S4B).
Mapping of the interaction domains revealed that the amino-
terminal half of MDM2, but not the p53-binding region, is
required for binding EZH2 and SUZ12 (Figures 4D and S4C–
S4H). When overexpressed, EZH2 and SUZ12 (as well as an
EZH2mutant lacking the catalytic SET domain, EZH2DSET) relo-
calized MDM2 to specific subnuclear structures (Figures S4I–
S4K), similar to Tip60 (Dohmesen et al., 2008) (Figure S4I), further
arguing that both can interact withMDM2. Nutlin3a, a compound
which targets the p53-binding domain ofMDM2, did not interfere
with the MDM2-EZH2 interaction (Figure S4L).
Finally, we asked whether MDM2 associates with the chro-
matin of PRC2-controlled and MDM2-coregulated genes. Chro-
matin immunoprecipitation (ChIP) of MDM2 from SJSA cells was
followed by targeted PCRof H3K27me3-enriched transcriptional
start sites (TSSs). Indeed, MDM2 bound specifically to the pro-
moters of PRC2/MDM2-responsive genes but neither to the
negative control genes MYO or GAPDH nor to PRC2 target
genes that were not coregulated by MDM2 (Figures S4M and
S4N; cf. Figures 3C–3F and Table S6). Importantly, MDM2-chro-
matin association was decreased to background levels following
EZH2 depletion (Figures 4E and S4O), strongly suggesting that
MDM2 recruitment to chromatin requires EZH2. In accordance,
Gal4-DNA binding domain-fused EZH2was capable of recruiting
MDM2 to a Gal4-binding DNA element (Figures 4F and S4P).
Thus, MDM2 binds to chromatin through its association with
PRC2.
Mdm2 Enhances Histone 3 Lysine 27 Trimethylation at
PRC2 Target Genes
PRC2 triggers the trimethylation of H3K27. We therefore investi-
gated the extent of this modification by ChIP at Mdm2-regulated
genes (cf. Figures 1B–1D), in p53/MEFs that were Mdm2+/+,(D) Gene sets regulated by both MDM2 and EZH2 are depicted in Venn diagram
opposite regulation.
(E and F) qRT-PCR analysis of selected genes (mean ± SEM, n = 3).
See also Figure S3 and Table S1, Table S3, Table S4, and Table S6.
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reduction of H3K27me3 at the TSSs of Hox genes when
removing or mutating Mdm2 (Figure 5A). The activation of tran-
scription in response to the removal of a repressive mark is
frequently associated with the formation of a nucleosome-free
region. Consistently, ChIP analysis of total histone H3 revealed
decreased H3 occupancy at some PRC2 target promoters, but
to a lesser extent compared to the occupancy by H3K27me3
(Figure S5A). Interestingly, the reduction of H3K27me3 was not
accompanied by reduced PRC2 recruitment, (Figure 5B). The to-
tal amounts of EZH2 present in the cells were not found to be
affected by the Mdm2 status, nor was the interaction of the
PRC2 members with each other (analyzed in MEFs and
HCT116 cells), whereas the global levels of H3K27me3 were
somewhat reduced in the absence of Mdm2 (Figures S5B–
S5D). In agreement, overall H3K27me3 (by ChIP-Seq analysis)
was only mildly reduced in p53/Mdm2/ MEF cells (Fig-
ure S5E; Table S2). However, a set of specific regions, mainly
near TSSs, was differentially methylated to a greater extent (Fig-
ure S5F). The majority of these regions showed decreased
H3K27me3 upon loss of Mdm2 (Figures 5C, 5D, and S5G; Table
S7). The genes that we had previously identified as upregulated
by Mdm2 knockout (cf. Figure 1B and Table S2) showed a lower
degree of H3K27me3 when Mdm2 was removed, whereas
downregulated genes revealed increased methylation (Fig-
ure 5E). Taken together, Mdm2 enhances the activity, but not
the amount, of PRC2 tomediate H3K27 trimethylation at specific
genes.
Mdm2 Contributes to the Monoubiquitination of Histone
2A at Lysine 119 at Its Target Genes
H3K27me3 is no longer considered a unidirectional prerequisite
for H2AK119monoubiquitination (H2AK119ub1). Rather, the two
modifications enhance the occupancy of one another on chro-
matin to maintain stemness (Kalb et al., 2014). We therefore
determined the impact of Mdm2 on the degree of H2A monoubi-
quitination at K119.
Indeed, p53/Mdm2/ or p53/Mdm2CA/CA MEFs dis-
played a highly significant reduction in H2AK119ub1 at the
TSSs of PRC2/Mdm2-regulated target genes, as compared to
p53/ MEFs (Figure 6A). In contrast, the amounts of the E3
ligase component of PRC1, RING1B, were increased on most
of these genes (Figure 6B). We propose that the discrepancy be-
tween PRC1 recruitment and diminished H2AK119 ubiquitina-
tion may result from an inactive Ring1B conformation, e.g.,
through interaction with additional PRC1 components (Taherb-
hoy et al., 2015) or through impaired ubiquitination of Ring1B
itself (Ben-Saadon et al., 2006). Similar ChIP results were ob-
tained from HCT116 cells lacking p53, upon removal of MDM2
by siRNA (Figures S6A and S6B), but not in wild-type HCT116
cells after depleting p53 (Figure S6C). Overall H2AK119ub1
levels were moderately reduced in MEFs (Figure S6D) but not
HCT116p53/ cells (Figure S6E). Notably, the disruption ofs to show the overlap of co-regulated genes and the absence of genes with
Figure 4. MDM2 Interacts with the PRC2 on Chromatin
(A) Endogenous MDM2, EZH2, and SUZ12 were coimmunoprecipitated from MG132-pretreated SJSA cells. Cell lysates (Input) and the immunoprecipitated (IP)
material were analyzed by immunoblotting (IB).
(B and C)Wild-typeMDM2was overexpressed by transfection, together with HA-tagged EZH2 (B) or Flag-tagged SUZ12 (C) in H1299 cells, followed by IP and IB
as in (A). Note that the Input in (B) was obtained after the addition of antibodies, explaining the appearance of an IgH band. Endogenous MDM2 was below the
detection limit.
(D) Domain mapping of the MDM2 interaction with EZH2, graphically summarized from Figures S4C–S4H.
(E) PRC2 recruits Mdm2 to chromatin. Chromatin immunoprecipitation (ChIP) analysis of MDM2 on PRC2 target gene promoters after SJSA cells were trans-
fected with siEZH2 or siControl (enrichment over IgG background; mean ± SEM; n = 3).
(legend continued on next page)
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the Mdm2 RING finger domain, which is essential for Mdm2
ubiquitin ligase activity (Honda et al., 1997; Honda and Yasuda,
2000), led to a similar reduction in H2AK119ub1 occupancy of
promoters, compared to the entire removal of Mdm2 (Figures
6A). This may suggest that Mdm2 directly ubiquitinates
H2AK119 in vivo, as previously suggested by its ability to do
so in vitro (Minsky and Oren, 2004).
ChIP-Seq analysis of p53/ MEFs versus p53/Mdm2/
MEFs identified a remarkable overall change (mostly a reduction
upon Mdm2 deletion) of H2AK119ub1 near TSSs (Figures 6C,
6D, S6F, and S6G; Table S2 and Table S7), and especially at
Mdm2-responsive genes (Figure 6E; cf. Figure 1B). TSSs with
reduced H3K27me3 strongly overlapped with those showing
reduced H2AK119 ubiquitination, whereas not a single gene
was foundwith opposite regulation of the twomodifications (Fig-
ures 6F, 6G, and S6H). These genes were enriched for annota-
tions in development and differentiation (Table S7). This strongly
argues that Mdm2 regulates PRC2 target genes by promoting
the positive feedback between H3K27me3 and H2AK119ub1.
Simultaneous Depletion of MDM2 and RING1B/RNF2
Cooperatively Impairs Gene Repression and Cell
Proliferation
MDM2 (Figure 6) as well as the PRC1 component RING1B, also
known as RNF2 (Wang et al., 2004), each contribute to H2AK119
monoubiquitination, prompting us to examine the consequences
of their simultaneous loss. RING1B was stably knocked down in
both p53/ and p53/Mdm2/ MEFs (Figure S7A), and gene
expression analyses were performed. Notably, the prototypical
PRC2-target genes Hoxb13, Hoxc10, and Hoxc13 (cf. Figure 1)
were all upregulated by the removal of either Mdm2 or Ring1B.
Moreover, the simultaneous elimination of Mdm2 and Ring1B
generally led to a further enhancement of gene expression (Fig-
ure 7A). Strikingly, Ring1B depletion in p53/Mdm2/ cells
(but not in p53/ cells) resulted in a severe block in cell prolifer-
ation (Figures 7B and 7C), arguing that the elimination of Mdm2
and Ring1B synthetically abolishes cell growth. Similarly, simul-
taneous knockdown of MDM2 and RING1B decreased cell
viability much more profoundly than single knockdowns in
HCT116 p53/ cells (Figures 7D, 7E, and S7B). Nonetheless,
and in contrast to the MEF system, enough HCT116p53/ cells
were retrieved from the double knockdown to perform ChIP
analysis. And indeed, we detected a further loss of
H2AK119ub1 on MDM2/PRC2 target genes (Figure 7F) when
simultaneously knocking down MDM2 and RING1B. Thus, at
least one of these E3 ligases is required for the repression of
PRC2-regulated genes and the maintenance of cell proliferation.
DISCUSSION
MDM2 suppresses gene expression patterns associated with a
differentiated cell phenotype, independent of p53. This function
is required for induced pluripotency, to suppress osteoblast dif-(F) Mdm2 is recruited to the heterologous promoter by EZH2. HEK293 cells carr
contained a tetracyclin-inducible expression cassette for EZH2 fused to the Gal4
addition and transient overexpression of MDM2, ChIP was performed with antib
See also Figure S4.
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port the proliferation of cancer cells. At least one key mechanism
to achieve this relies upon a functional interaction between
MDM2 and the Polycomb Repressor Complex 2, leading to a
repressive chromatin state by enhanced H2AK119 monoubiqui-
tination and H3K27 trimethylation.
MDM2 may provide a means to couple H2AK119ub1 with
H3K27me3 by the physical association of MDM2 with PRC2.
This may be required for proper coordination of the two modifi-
cations, since only a minority of the heterogenous PRC1 com-
plexes is recruited by H3K27me3 (Gao et al., 2012). Like
Mdm2, the E3 ligase TRIM37 associates with PRC2 and medi-
ates H2AK119 ubiquitination (Bhatnagar et al., 2014), suggesting
a similar biological function.
PRC2 also associates with regulatory partners that define its
activity and promoter specificity. These include JARID2 (Peng
et al., 2009), ASXL1 (Abdel-Wahab et al., 2012), GATA4 (He
et al., 2012), BRCA1 (Wang et al., 2013), and noncoding RNAs
(Kaneko et al., 2014), specifying themechanisms controlling line-
age-specific genes. The recruitment and regulatory activity of
PRC2 is cell type dependent and subject to complex mecha-
nisms including the repertoire of transcription factors expressed
(Simon and Kingston, 2013), perhaps explaining the largely
distinct sets of genes regulated by PRC2 and MDM2 that we
observed in MEFs, MSCs, and cancer cells.
Likewise, MDM2 recruitment to specific promoters may be
enhanced through the simultaneous interaction of MDM2 with
PRC2 and additional factors known to bind MDM2, including
the acetyl transferases Tip60 (Legube et al., 2002) and p300
(Grossman et al., 1998), or the transcription factors E2F1 (Zhang
et al., 2005), ATF3 (Mo et al., 2010), p73 (Dobbelstein et al.,
1999), and, when present, p53 (Oliner et al., 1992). Additional
binding factors, such as p14ARF (Sherr, 1998), can be expected
to regulate MDM2-mediated H2A monoubiquitination.
What could be the evolutionary purpose of coupling the p53-
antagonism and an essential helper function in pluripotency to
the same molecule, i.e., MDM2? One explanation may be that
this allows stem cells to respond more efficiently to genotoxic
stress. MDM2 is phosphorylated (Maya et al., 2001) and destabi-
lized (Stommel and Wahl, 2004) in response to DNA damage,
and this is essential for p53 activation in vivo (Gannon et al.,
2012). DiminishingMDM2 function and/or levels upon DNA dam-
agemay induce a dual response in stem cells, i.e., p53 activation
and dysregulation of PRC2 target genes to counteract stemness
and avoid cancerogenesis.
It has long been suspected that MDM2 may carry out p53-in-
dependent functions. The artificial overexpression of MDM2 in-
terferes with cell proliferation independent of p53 (Brown et al.,
1998) and induces replicative stress (Frum et al., 2014), largely
precluding add-back experiments in our deletion studies. None-
theless, the concepts of p53-independent, physiological roles of
MDM2 were discouraged by the fact that, at first glance,
p53/Mdm2/ mice do not show significant differences inying an integrated upstream activation sequence (UAS) that binds Gal4 either
DNA binding domain, or a control gene (Hansen et al., 2008). Upon tetracyclin
odies to EZH2 and MDM2, followed by amplification of the UAS.
Figure 5. Mdm2 Is Required for H3K27 Trimethylation at Transcription Start Sites
(A and B) p53/, p53/Mdm2/, and p53/Mdm2CA/CA MEFs were subjected to targeted H3K27me3 (A) and EZH2 ChIP (B). ChIP levels around the TSSs of
Mdm2/PRC2 target genes are shown as % of Input normalized to p53/ cells; mean ± SEM, nR 4.
(C and D) H3K27me3 ChIP-Seq from p53/ and p53/ Mdm2/ MEFs (n = 4). Differentially methylated TSSs were aggregated around the TSSs.
(E) In comparison with the gene expression levels (RNA-Seq; Figure 1B; Table S2), relative H3K27me3 enriched genomic sites for either upregulated (UP),
downregulated (DOWN), or nonregulated (non-reg.) genes were evaluated comparing p53/ Mdm2/ to p53/ MEFs.
See also Figure S5, Table S2, and Table S7.
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phenotype when compared to p53/Mdm2+/+ mice (Jones
et al., 1995; Montes de Oca Luna et al., 1995). However, it has
now become clear that a lack of p53 hinders the development
of at least a fraction of the animals, reaching from the implanta-
tion of embryos (Hu et al., 2007) to the proper closure of the neu-
ral tube (Armstrong et al., 1995; Sah et al., 1995). Even more
functions of p53 may become observable under conditions of
stress, such as infectious diseases, malnutrition, or genotoxic
agents within food. Such conditions are largely absent in labora-
tory animals. p53-independent functions of MDM2 may hitherto
have escaped observation for similar reasons. They may also
become evident through the simultaneous deletion of other
H2AK119 E3 ligases.
A finding of potential medical importance consists in the fact
that not only benign stem cells rely on the p53-independent func-
tion of MDM2, but that the same is true in tumor cells that lack
p53, at least in the systems studied here. This is in agreement
with other oncogenes that support pluripotency and also pro-
mote cancer. Examples include oncogenes that favor epithe-
lial-mesenchymal transition (EMT), such as b-catenin, Twist,
Ras, and Myc, all of which confer stem cell properties as well
(Gupta et al., 2009).
Tumor cells face a number of stress conditions (Dobbelstein
and Moll, 2014), and replicative stress with enhanced DNA dam-
age plays a particularly prominent role (Dobbelstein and Søren-
sen, 2015). It is conceivable that such stress conditions raise
the need for additional mechanisms in order to maintain stem-
ness. Indeed, induced pluripotent stem cells from Li Fraumeni
patients can transform into cancer cells in an in vitro model
(Lee et al., 2015), further strengthening the connection between
induced pluripotency and cancer development. MDM2 un-
dergoes specific modifications in response to replicative stress
and DNA damage (Wade et al., 2013), and it associates with
damage response factors such as the MRN complex (Bouska
and Eischen, 2009). We propose that the in vivo function of
MDM2 in stem cell maintenance may become more prominent
in the context of cancer formation, explaining why cancer cells
appear to requireMDM2 evenwhen p53 is absent ormutant (Fig-
ure 3). This is further supported by the identification of cancers
that simultaneously show amplifications of the MDM2 gene
and mutations of p53 (Forslund et al., 2008), or tumors with
simultaneous mutations of the MDM2 antagonist p14ARF as
well as p53 (Sanchez-Cespedes et al., 1999), arguing that
MDM2 may contribute to tumor progression even when p53 is
no longer active. From a therapeutic perspective, it may there-
fore be advisable to target MDM2 not only by drugs that interfereFigure 6. Loss of Mdm2 Simultaneously Depletes H2AK119ub1 and H3
(A and B) p53/, p53/Mdm2/, and p53/Mdm2CA/CAMEFs were subjected
5B. Mean ± SEM, nR 4.
(C) H2AK119ub1 ChIPSeq, aggregated around TSSs.
(D) Differentially ubiquitinated sites around TSSs (cf. Figure 5C and Table S7).
(E) In comparison to the gene expression levels (Figure 1B and Table S2), rela
nonregulated (non-reg.) genes were evaluated, comparing p53/ Mdm2/ to p
(F) Overlap of differentially bound (DB) regions from H3K27me3 and H2AK11
(dko < sko) or upregulated (dko > sko) in p53/ Mdm2/ compared to p53/
(G) Genomic binding profiles for H3K27me3 and H2AK119ub1 at the HoxC10 locu
Mdm2/).
See also Figure S6, Table S2, and Table S7.with the MDM2-p53 interaction. Such drugs are unlikely to over-
come the cooperation of MDM2 with the PRC2 (Figure S4L).
Instead, it may prove useful to either destabilize MDM2 alto-
gether by enhancing its autoubiquitination function (Qin et al.,
2015; Wang et al., 2014b), or otherwise to inhibit the function
of its RING finger domain (Yang et al., 2005). Indeed, the
MDM2-destabilizing compound SP-141 was found to interfere
with the proliferation of tumor cells even when p53 was mutant
(Wang et al., 2014a).We propose thatMDM2-destabilizing drugs
not only restore p53 activity (when p53 is wild-type) but also
interfere with the functions of MDM2 in the support of polycomb
repressors, in chromatin modification, and in cancer cell
renewal.
EXPERIMENTAL PROCEDURES
Detailed descriptions are provided in Supplemental Experimental Procedures.
Induction of pluripotency, differentiation into osteoblasts, and cell transfec-
tions were carried our according to standard protocols. Array hybridization
(Agilent) and deep sequencing (Illumina) were performed by the Transcriptome
Analysis Laboratory (TAL) at Univerity Medical Center Go¨ttingen. Immunopre-
cipitations were carried out in the presence of 300 mM NaCl, 0.5% NP40, and
0.1% sodium deoxycholate. Statistical testing was performed using Graph
Pad Prism 6. Significance levels are indicated: ***p % 0.001; **p % 0.01;
*p% 0.05.
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Figure 7. Simultaneous Elimination of MDM2 and RING1B/RNF2 Synthetically Interferes with Gene Repression and Cell Proliferation
(A) p53/ and p53/ Mdm2/ MEFs were each transduced to knock down Ring1B by shRNA. qRT-PCR analysis reflected the induction of PRC2-regulated
genes.
(B and C) The cells from (A) were counted 2 days after plating, revealing compromised proliferation of cells that lack both Mdm2 and Ring1B.
(D) HCT116 p53/ cells were depleted of MDM2 and/or RING1B by transfection of siRNA and retransfection at 48 hr. Changes in cell morphology and number
were documented by phase contrast microscopy 96 hr after the first transfection.
(E) The area covered by cells giving rise to phase contrast (cf. D) was quantified in each case, revealing significant differences between the combined depletion of
MDM2 and RING1B and all other siRNA transfections.
(F) The same cells were used for H2AK119ub1 ChIP on target gene promoters.
See also Figure S7.
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